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THE COMPLEMENT SYSTEM: PATHWAYS OF ACTIVATIONS AND 
FUNCTIONS 
Jelena Antić-Stanković1, Sanja Stanković2 
The complement system plays an important role in host defense. It is composed of 
series of plasma proteins which, when activated in a sequential reaction, unleashes a 
powerful destructive activity towards invading pathogens. Three major pathways exist in 
the activation of complement: the classical pathway, which is initiated by antibody-antigen 
binding, the alternative pathway, which is activated by a susceptible foreign surface, and 
the lectin pathways, which can be triggered by manann-binding lectins. 
The complement system consists of serum and cell surface proteins that interact 
with one another and with other molecules of the immune system in a highly regulated 
manner. Complement proteins are plasma proteins that are normally inactive and they are 
activated only under particular conditions to generate products that mediate various 
effector functions of the complement. Acta Medica Medianae 2017;56(1):50-55.  
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Introduction 
Complement is a part of the innate immune 
system. It is now known that complement is a 
system of more than 30 different plasma and 
membrane proteins. It has three physiological 
activities: defending against pyogenic bacterial 
infection, bridging innate and adaptive immunity 
during the classical pathway of complement 
activation, disposing of immune complexes and 
the products of inflammatory injury. Complement 
may be activated by three different mechanisms, 
known as the classical, alternative, and lectin 
pathways (1). 
Classical pathways of complement acti-
vation 
H The classical pathway is initiated by bin-
ding of the complement protein C1 to the CH2 
domains of IgG or CH3 domains of IgM molecules 
that have bound antigen. 
C1 (750 kDa) is a large, multimeric protein 
complex composed of C1q, C1r, and C1s subunits. 
C1q subunit, molecular weight of 460 kDa, is a 
hexamer of three pairs of chains (22, 23 and 24 
kDa), made up of an umbrella-like radial array. 
The globular heads at the end of each chain are 
the contact regions for immunoglobulin. The C1q 
molecule must bind to two Ig heavy chains to be 
activated.  
C1r (85 kDa, dimer) and C1s (85 kDa, di-
mer) are serine esterases that function as a 
tetramer containing two molecules of each. Bin-
ding of two or more of the globular heads of C1q 
to Fc regions of IgG or IgM leads to enzymatic 
activation of the associated C1r, which cleaves and 
activates C1s. Activated C1s cleaves the next pro-
tein in the cascade, C4 component into larger C4b 
and smaller C4a fragments (2,3).  
C2 (102 kDa, monomer), the next com-
ponent, is then cleaved into larger C2a fragment, 
and smaller C2b fragment, by C1s. C2a attaches 
noncovalently to C4b, forming a C4aC2a complex 
that is termed as a classical pathway C3 con-
vertase (3).  
C3 component (185 kDa) consists of α (110 
kDa) and β (75 kDa) subunits. Cleavage of C3, by 
C3 convertase, results in the removal of a small 
C3a fragment, which leaves C3b. A larger frag-
ment, C3b, also contains a thioester bond, there-
fore, C3b can also be covalently attached to the 
surface of the antigenic target, to immunoglobulin. 
Once C3b is deposited, it can bind factor B and 
generate more C3 convertase by the alternative 
pathway. Some of the C3b molecules generated 
by the classical pathway C3 convertase bind to the 
complex C4bC2a. This complex functions as the 
classical pathway C5 convertase which cleaves C5 
into the C5a and C5b If these bonds are not 
formed, the C3b remains in the fluid phase, its 
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thioester is quickly hydrolyzed, and it becomes 
inactive and complement activation stops (4). 
 
Alternative pathway of complement 
activation 
 
The alternative pathway differs from the 
classical pathway by its mechanism of initial 
activation. Some substances, such as polysac-
charides, endotoxins, virally infected cells (influ-
enza, Epstein-Barr virus), yeast cells wall extracts 
(zymosan) and some immunoglobulin light chains 
can serve to promote alternative pathway acti-
vation.  
Under certain circumstances, the alternative 
pathway has the capacity to autoactivate because 
normally C3 in plasma is being continuously 
cleaved at a low rate to generate C3b in a process 
that is marked as ”C3 tickover” (5). An internal 
thioester bond in C3 becomes unstable when the 
molecule is cleaved, and it reacts with the amino 
or hydroxyl groups of cell surface proteins or 
polysaccharides to form amide or ester bonds. In 
this case, the complement is activated by alter-
native pathway. If these bonds are not formed, 
C3b remains in the fluid phase, its thioester is 
quickly hydrolyzed, and it becomes inactive and 
complement activation stops.  
After binding to the surface of microorga-
nisms, C3b binds a plasma protein called factor B. 
After it is bound, factor B is cleaved by a plasma 
serine protease called factor D to generate a 
smaller Ba fragment and larger Bb fragment 
(remains attached to C3b). The C3bBb complex is 
the alternative pathway C3 convertase. In ad-
dition, another protein of the alternative pathway, 
called properidin, can bind to and stabilize the 
C3bBb complex. Some of the C3b molecules 
generated by the alternative pathway C3 con-
vertase bind to the convertase itself. This results 
in the formation of a C3bBbC3b complex which 
functions as the alternative pathway C5 conver-
tase to cleave C5 and initiate the late steps of 
complement activation (2, 6). 
 
Lectin pathway of complement activa-
tion 
 
Lectin pathway of complement activation is 
induced by binding of manose residues on the 
surface of mocroorganisms to soluble complex 
that consists of mannose-binding lectin (MBL), 
enzyme inert protein molecular weight of 19 kDa 
and three specific serin esterase (mannose-
binding lectin associated serin proteases, MASPs 
1, 2, and 3). This complex is structurally similar to 
C1 component of the complement (7-9). 
MBLs consist of three polypeptide chains, all 
containing collagen-like domain and the 
carbohydrate recognition domain (CRD). That 
binds specifically to mannose or N-acetylgluco-
samine, placed at the surface of microorganisms. 
Afterwards, the complex MBL-MASPs can activate 
C4 and C2 components of the complement. MASP1 
can also directly activate C3 component of the 
complement (1, 10-12).  
 
Late steps of complement activation 
 
Common to all pathways of complement 
activation is the formation in the certain moment 
of C5 convertase (serin esterase) that degrades 
C5 (190 kDa, dimmer) component of the com-
plement to the smaller C5a, and the larger, C5b 
fragment.  
One interesting difference between the early 
activation pathway and the later components of 
complement (after C5) is the absence of proteolitic 
activity in the later components.  C6 through C9 
assembly is the product of conformational changes 
that exposes new reactive sites on each new com-
plement component. 
C5b fragment remains bound to the cell 
surface. The remaining components of the 
complement cascade, C6, C7, C8, and C9, are 
structurally related proteins without enzymatic 
activity. C5b transiently maintains a conformation 
cascade, C6, and the stable C5bC6 complex 
remains loosely associated to the cell membrane 
until it binds a single C7 molecule.  
The C7 component of the resulting C5bC6C7 
complex is hidrofobic, and it inserts into lipid 
bilayer of cell membranes, where it becomes a 
high-affinity receptor for one C8 molecule (155 
kDa, trimer). Activation of this complex is com-
plete after binding C9 component (79 kDa, 
monomer). C9 is a serum protein that polymerizes 
at the site of the bound C5bC6C7C8 complex and 
forms pores in plasma membranes. C9 is structu-
rally homologous to perforin (3).  
Complex C5bC6C7C8C9 is called membrane 
attack complex (MAC) or terminal complement 
complex (TCC). MAC leads to the lysis of cells, by 
forming on the cell membrane pores with diameter 
about 1 nm that form channels allowing free mo-
vement of water and ions (13).  
 
Functions of complement 
 
The principal effector functions of the 
complement system in innate immunity and spe-
cific humoral imunity are to promote phagocytosis 
of microbes on which complement is activated, to 
stimulate inflammation, and to induce the lysis of 
these microbes. In addition, products of comple-
ment activation provide "second signals" for the 
activation of B lymphocytes and the production of 
antibodies (3). 
The proteolytic complement fragments C5a, 
C4a and C3a are called anaphylatoxins and induce 
acute inflammation by acting on mast cells and 
neutrophils. All three peptides bind to mast cells 
and induce degranulation, with the release of va-
soactive mediators such as histamine. In neutro-
phils, C5a stimulates chemotaxis, film adhesion to 
endothelial cells, and at high doses, stimulation of 
the respiratory burst and production of reactive 
oxygen intermediates. In addition, C5a may act 
 51 
The complement system: pathways of activations and functions                                                          Jelena Antić-Stanković at al. 
directly on vascular endothelial cells and lead to 
increased vascular permeability and the expres-
sion of P-selectin, which promotes neutrophil bin-





Type 1 complement receptor (CR1, CD35) is 
a member of a large family of C3- and C4-binding 
proteins known as the regulators of complement 
activation (RCA). CR1 is expressed on human ery-
throcytes, monocytes, polimorphonuclear cells, B 
and T lymphocytes, eosinophils and follicular den-
dritic cells.  
Soluble forms of CR1 in serum and urine ha-
ve been described. 
The major form of CR1 is a 190 kDa protein, 
although less frequent allelic forms of 160, 220 
and 250 kDa have also been described (15). 
The major role of CR1 on erythrocytes is the 
trapping of circulating immune complexes and the 
subsequent transfer of these complexes to Kupffer 
cells and macrophages in the liver and spleen.  
CR1 promotes phagocytosis by monocytes 
and neytrophils of targets that are also coated 
with Ig, thereby functionally interacting with Fc 
receptors (16). 
Type 2 complement receptor (CR2, CD21) is 
a protein with molecular weight of 145 kDa. CR2 is 
present on B lymphocytes, follicular dendritic cells, 
a small subset of T lymphocytes, thymocytes, epi-
thelial cells, basophils, and keratinocytes. It spe-
cifically binds the cleavage products of C3b: C3b 
and C3dg. It also serves as the receptor for the 
Epstein-Barr virus (15, 17).  
The major role of CR2 on B lymphocytes is 
to serve as a costimulator that acts by amplifying 
antigen-induced B cell activation through surface 
IgM. CR2 coassociates on the cell membrane with 
a B-lymphocyte-specific protein designated CD19, 
CD81, Leu13, MHC II and γ-glutamyl trans-
peptidase (GGT). This complex delivers signals to 
B cells that enhance the responses of B cells to 
antigen. This complex also regulates the ho-
motypic adhesion of cells. Coligation of CD19 or 
CR2 strongly promotes B-limphocyte activation 
(18). 
Type 3 complement receptor (CR3, Mac-1, 
CD11b/CD18) is a heterodimer (165 kDa) and 
belongs to the β2-integrin family. CR3 consists of 
an α chain (CD11b) noncovalently linked to the β 
chains (CD18). CR3 is expressed primarily by 
neutrophils, monocytes, follicular dendritic cell, 
Kupffer cells, and NK cells.  CR3 is a receptor for 
C3 and C3 fragments. The affinity for the C3 frag-
ments varies, with C3bi>C3b>C3d. CR3 plays an 
important role in the phagocitosis of C3bi coated 
particles (19). 
Type 4 complement receptor (CR4, CD11c/ 
CD18) is an another member of β2-integrin family. 
CR4 is expressed by dendritic cells, neutrophyls  
 
 
and NK cells. CR4 also binds C3bi >C3b but its 
biologic activities are similar to CR3 (19). 
C1q receptor is expressed on macrophages, 
endothelial cells, fibroblasts, platelets, epithelial 
cells and leukocytes. Although four receptors for 
C1q have been described, only one of them ap-
pears to function as a typical transmembrane 
receptor. This is C1qRp (C1q receptor-related pro-
tein). C1qRp is a transmembrane protein expres-
sed on monocytes, macrophages, platelets and 
endothelial cells. The receptor interacts with C1q 
collagen-like tails and MBL. C1qRp can enhance 
CR1 mediated phagocytosis (20, 21). 
C5a receptor (CD88) is an approximately 50 
kDa transmembrane-spanning protein expressed 
on mast cells, PMN, macrophages, monocytes, T 
cells, eosinophils, hepatocytes, vascular endothe-
lium, astrocytes, bronchial, and alveolar epithelial 
cells (22, 23).  
C3a receptor is transmembrane-spanning 
protein (60 kDa) expressed on PMN, monocytes, 
and basophils (23). 
 
Regulation of the complement system 
 
Mammals possess several mechanisms to 
protect bystander cells of the deleterious effects of 
autologous complement activation. These pro-
tective mechanisms involve serum and membrane 
molecules (complement regulatory proteins), 
which specifically recognize and inactivate com-
ponents of the classical, alternative or lectin 
pathways of complement activation. They protect 
autologous cells from complement damage either 
by restricting C3 cleavage and its deposition or by 
inhibiting MAC formation. Several membrane-
bound complement regulators in humans have 
been characterized: decay-accelerating factor 
(DAF, CD55), membrane cofactor protein (MCP, 
CD46), CD59, complement receptors 1 (CR1, 
CD35) and 2 (CR2, CD21). These molecules be-
long to a family of structurally and genetically re-
lated proteins named regulators of complement 
activation (RCA) and contain homologous repe-
titive domains (short consensus repeats, SCR) 
which are responsible for the protective function 
against autologous complement activation (24, 
25). 
The complement proteins interact with other 
endogenous molecules to keep microbes from en-
tering the parenteral tissues. One of the mucosal 
proteins known to interact with the early comple-
ment components of both the classical and the 
lectin pathway is the salivary scavenger and 
agglutinin (SALSA). SALSA is also known as 
deleted in malignant brain tumors 1 and gp340. It 
is found both attached to the epithelium and 
secreted into the surrounding fluids of most 
mucosal surfaces. SALSA has been shown to bind 
directly to C1q, mannose-binding lectin, and the 
ficolins. Through these interactions, SALSA re-
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Complement system in disease 
 
The complement system may be involved in 
different human disease. 
Defficiencies in any components of comple-
ment (C1q, C1r, C2, C3, C4) may lead to ab-
normal patterns of complement activation. If 
normally generated immune complexes are not 
cleared from the circulation, they may be de-
posited in blood vessel walls and tissues, where 
they activate leukocytes and produce local inflam-
mation (29).  
C2 and C4 deficiencies are not usually as-
sociated with increased susceptibility to infections, 
which suggests that the alternative pathway is 
adequate for host defense against most microbes. 
Deficiency of C3 is associated with frequent seri-
ous pyogenic bacterial infections and this illustra-
tes the importance of C3 for opsonization and 
phagocytosis. Deficiencies in components of the 
alternative pathway result in increased suscepti-
bility to infection with pyogenic bacteria.  
Deficiencies in the terminal complement 
components (C5, C6, C7, C8, C9) have also been 
described. Interestingly, the only consistent cli-
nical problem in these patients is infection by 
Neisseria bacteria.  
Deficiencies in CR3 and CR4 both result from 
mutations in the genes. This disorder is characte-
rized by inadequate adherence of neutrophils and 
perhaps by impaired C3b dependent phagocytosis 
of bacteria (17). 
Even when it is properly regulated and ap-
propriately activated, the complement system can 
cause significant tissue damage. In some situa-
tions, complement activation is associated with 
intravascular thrombosis and can lead to ischemic 
injury to tissues. For instance, anti-endothelial 
antibodies against vascularized organ transplants 
may bind to vascular endothelium and activate 
complement, thereby leading to the generation of 
MAC and damage to the endothelial surface, which 
favors coagulation. There is also evidence that 
some of late complement proteins may activate 
prothrombinases (30).  
Systemic vasculitis and glomerulonephritis 
result from the deposition of immune complexes in 
the walls of vessels and kidney glomeruli. Comple-
ment activated by the immunoglobulin in these 
deposited immune complexes initiates the acute 
inflammatory responses that destroy vessels walls 




During an infection, complement leads to in-
flammation, opsonization, phagocytosis, and des-
truction of the pathogen, and ultimately results in 
activation of the adaptive immune response. Both 
inefficient and overstimulation of the complement 
can be detrimental for the host and are associated 
with increased susceptibility to infections or non-
infectious diseases, including autoimmunity, chro-
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Sistem komplementa ima značajnu ulogu u odbrani domaćina od patogena. Sastoji 
se od niza proteina plazme koji se aktiviraju u kaskadnom procesu, dovodeći do 
oštećenja patogena. Opisana su tri puta aktivacije sistema komplementa: klasičan 
(aktivira se vezivanjem C1q komponente komplementa za kompleks antigen-antitelo), 
alternativni (aktivira se direktnim vezivanjem C3b komponente komplementa za 
površinske molekule mikroorganizama) i lektinski (indukovan je vezivanjem manoza 
vezućeg proteina za manozne rezidue na površini mikroorganizama). 
Najvažnija uloga sistema komplementa u urođenom i specifičnom imunitetu je 
stimulisanje fagocitoze, liza mikroorganizama i pospešivanje inflamacije. Komplement 
ima ključnu ulogu i u uklanjanju imunskih kompleksa. Acta Medica Medianae 
2017;56(1):50-55. 
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